

Annotated IVIR-AC Agenda 2018 (draft 14 September 2018)

Monday, 24 September 2018

Time	Session	What will be presented?	What are the questions?	AC reviewers and WHO focal points
12.30-12.45	Welcome	Charge of the Committee		R. Breiman
<i>THEME 1: Research to minimize barriers and improve coverage of vaccines currently in use</i>				
12.45-14.15	<i>Session 1:</i> Global vaccine demand and acceptance	<ul style="list-style-type: none"> - Introduction and context by L. Menning (10 min) - Update IVIR-AC WG on Vaccine Demand and Acceptance including generic framework on vaccine acceptance and demand by M. Weiss (15 min) - HPV vaccine demand and acceptance study protocol South-Africa by F. Scorgie (15 min) - IVIR-AC reviewers' comments (each 3 min) <p>Discussion (45 min)</p>	<ul style="list-style-type: none"> - Does IVIR-AC have any comments/suggestions to the proposed ToR of IVIR-AC working group? - Does IVIR-AC have any feedback on the generic vaccine acceptance and demand framework proposed? - Does IVIR-AC have any feedback on the study protocol on vaccine demand and acceptance from South-Africa? 	<p>IVIR-AC members: V. Nankabirwa J-D. Lelièvre</p> <p>WHO focal point: L. Menning</p>

Time	Session	What will be presented?	What are the questions?	AC reviewers and WHO focal points
THEME 2: Research to conduct impact evaluation of vaccines in use				
14.15-15.30	Session 2: Cervical cancer elimination model comparison	<ul style="list-style-type: none"> - Introduction by R. Hutubessy (5 min) - WHO's cervical cancer elimination roadmap by N. Broutet (10 min) - Introduction of Policy-1 model by K. Canfell (10 min <i>(by Webex)</i>) - Introduction of Harvard model by J. Kim (10 minutes) - Introduction of HPV-ADVISE model by M. Brisson (10 minutes) - Cervical cancer elimination model comparison exercise to inform the elimination targets and scenarios by J. Kim and M. Brisson (30 min) - IVIR-AC reviewers' comments (each 5 min) 	<ul style="list-style-type: none"> - Does IVIR-AC have any feedback on the modeling methods of the individual modeling groups? - Is there agreement on the collaborative model comparison work for defining the cervical elimination thresholds and the strategies towards global cervical cancer elimination? 	IVIR-AC members: P. Beutels D. Burke WHO focal point: R. Hutubessy
15.30-16.00	Coffee/tea break			
15.30- 17.00	Session 2 continued:	Discussion continued (90 min)		
17.00-17.30 17.30	Summary Day 1 Cocktail	Summary of key conclusions and next steps TBC		R. Breiman

Tuesday, 25 September 2018

Time	Session	What will be presented?	What are the questions?	AC reviewers and WHO focal points
08.30-10.00	Session 3: Total System Effectiveness (TSE)	<ul style="list-style-type: none"> - Introduction and context by A-L Khan (10 min) <i>(by WebEx)</i> - An update on TSE following the recommendations from IVIR-AC March 2018 by S. Botwright (15 min) - Country level dashboard to inform policy and monitoring progress by W. Panhuis (15 min) - IVIR-AC reviewers' comments (each 3 min) - Discussion (30 min) 	<ul style="list-style-type: none"> - Are all TSE recommendations from the IVIR-AC March 2018 meeting addressed? - Does IVIR-AC have any feedback the methods and tools used to support country level up take of vaccines and/or R&D decisions? - Does the IVIR-AC have any feedback on the TSE implementation activities of TSE in Indonesia, Thailand, Mali and Rwanda? - Does IVIR-AC have any feedback on the usefulness of country level dashboard and/or has suggestions for improvement? 	<p>IVIR-AC members : M. Jit A. Lopez</p> <p>WHO focal point: A-L. Khan</p>
10.00-10.30	Coffee/tea break			

Time	Session	What will be presented?	What are the questions?	AC reviewers and WHO focal points
10.30 – 11.45	Session 4: Measles Rubella vaccines investment case and timing of SIAs	<ul style="list-style-type: none"> - Introduction and context by A. Dabbagh (10 min) - Measles Rubella Investment Case by M. Jit (10') - An update of the timing of SIAs project following the recommendations from March 2018 by Mark Jit (10') - IVIR-AC reviewers' comments (each 3 min) Discussion (35 min) 	<ul style="list-style-type: none"> - Does IVIR-AC have any comments/suggestions on the update on the investment case and propose ways forward? - Are all SIA recommendations from the IVIR-AC March 2018 meeting addressed?? 	IVIR-AC members: Q. Bassat W. Orenstein WHO focal points: A. Dabbagh
11.45-12.45	Lunch			

Time	Session	What will be presented?	What are the questions?	AC reviewers and WHO focal points
12.45-14.00	Session 5: WHO Guide on typhoid vaccine cost-effectiveness	<ul style="list-style-type: none"> - Introduction and context by A. Bentsi-Enchill (10 min) - Presentation of WHO Guide by N. Chaiyakunapruk and G. Pitzer (20 min) - IVIR-AC reviewers' comments (each 3 min) - Discussion (30 min) 	<ul style="list-style-type: none"> - Does IVIR-AC has any feedback on the CEA guide for Typhoid vaccines, specifically on the modelling chapter? 	IVIR-AC members: S. Verguet W. Ndifon WHO focal point: A. Bentsi-Enchill
14.00-15.15	Session 6: Guidelines for multi-model comparisons	<ul style="list-style-type: none"> - Introduction and context by R. Hutubessy (5 min) - Model comparison guide by S. den Boon (15 min) IVIR-AC reviewers' comments (each 3 min) Discussion (30 min) 	<ul style="list-style-type: none"> - Does IVIR-AC have any feedback on the model comparison guide as a follow up from the IVIR-AC recommendations from May 2016? 	IVIR-AC members: D. Burke S. Verguet WHO focal point: R. Hutubessy
15.15-15.45	Coffee/tea break			

THEME 3: Research to improve methods for monitoring of immunization programs

15.45-17.00	Session 7: Using available data to identify areas of risk	<ul style="list-style-type: none"> - Introduction and context by A. Henao-Restrepo (5 minutes) - Pragmatic tool to identify immunization gaps by A. Acosta (15 minutes) - Options for risk analysis: Vaccine Decision Information Systems by W. Panhuis (15 minutes) 	<ul style="list-style-type: none"> Does IVIR-AC have any feedback on usefulness and methods used underlying the tools presented to identify areas of risk? 	IVIR-AC members: S. Sow M. Weiss WHO focal point: A. Henao-Restrepo
-------------	---	---	---	---

IVIR-AC reviewers' comments (each 3 min)

Discussion (30 min)

17.00-17.15	Summary Day 2	Summary of key conclusions and next steps	R. Breiman
17.15	<i>Adjourn</i>		

Wednesday, 26 September 2018

CLOSED SESSION FOR IVIR-AC MEMBERS ONLY

Time	Session	What will be presented?	What are the questions?	AC reviewers and WHO focal points
9.00-10.30	Formulation of IVIR-AC recommendations			
10.30-11.00	<i>Coffee/tea break</i>			
11.00 -12.30	Formulation of IVIR-AC recommendations			
12.30	<i>Adjourn</i>			